{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:46:11Z","timestamp":1747190771302,"version":"3.40.5"},"reference-count":24,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sixth Medical Center of PLA General Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Computational and Mathematical Methods in Medicine"],"published-print":{"date-parts":[[2022,7,13]]},"abstract":"<jats:p>Objective. To investigate the prognostic impact of computed tomography (CT) imaging big data-assisted arterial chemoembolization combined with iodine 125 (125I) seed implantation on patients with non-small-cell lung cancer (NSCLC). Methods. A total of 116 patients with intermediate and advanced NSCLC hospitalized in our hospital from August 2019 to August 2020 were selected and divided into a control group and an experiment group (58 cases in each group) by random number table method for the study. The patients in the experiment group were treated with CT imaging big data-assisted arterial chemoembolization combined with 125I seed implantation, while the patients in the control group were treated with arterial chemoembolization alone, with the use of gemcitabine combined with cisplatin (GP) in chemotherapy. The prognostic impact was determined by analyzing recent efficacy; the incidence of adverse effects; tumor size and CT perfusion parameters including blood volume (BV), blood flow (BF), and permeability surface (PS); frailty state and quality of life; and the levels of serum tumor markers including carcinoembryonic antigen (CEA), glycoconjugate antigen 125 (CA125), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), microRNA- (miRNA-) 137, and miR-379-5p. In addition, frailty status was evaluated using the Fried frailty phenotype (FP) scale, and quality of life was determined according to Karnofsky Performance Status (KPS) score. Kaplan-Meyer (KM) method was used to analyze the survival rate of NSCLC patients after a 12-month follow-up. Results. The remission rate in the experiment group (77.59%) was higher than that in the control group (56.90%) (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>P<\/a:mi>\n                        <a:mo>&lt;<\/a:mo>\n                        <a:mn>0.05<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>). Tumor size, BV, BF, PS, serum CEA and CA125 levels, and FP value in both groups were dramatically reduced after treatment compared with before treatment, especially in the experiment group after 1 and 3 months of treatment (<jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>P<\/c:mi>\n                        <c:mo>&lt;<\/c:mo>\n                        <c:mn>0.05<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>). Meanwhile, the serum miR-137 and miR-379-5p levels and KPS scores in both groups were higher after treatment than before treatment, especially in the experiment group after 1 and 3 months of treatment (<jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>P<\/e:mi>\n                        <e:mo>&lt;<\/e:mo>\n                        <e:mn>0.05<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula>). However, there was no significant difference in the incidence of nausea and vomiting, alopecia, diarrhea, myelosuppression, and hemoptysis of NSCLC patients in both groups after treatment (<jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>P<\/g:mi>\n                        <g:mo>&gt;<\/g:mo>\n                        <g:mn>0.05<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>). Further, the 12-month survival rate of NSCLC patients was higher in the experiment group (84.21%) than in the control group (64.29%) (<jats:inline-formula>\n                     <i:math xmlns:i=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M5\">\n                        <i:mi>P<\/i:mi>\n                        <i:mo>&lt;<\/i:mo>\n                        <i:mn>0.05<\/i:mn>\n                     <\/i:math>\n                  <\/jats:inline-formula>). Conclusion. CT imaging big data-assisted arterial chemoembolization combined with 125I seed implantation for NSCLC can improve recent efficacy and the prognosis of NSCLC patients by inhibiting tumor progression with a certain degree of safety.<\/jats:p>","DOI":"10.1155\/2022\/3472982","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T23:38:07Z","timestamp":1657755487000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Evaluation of CT Imaging Big Data-Assisted Arterial Chemoembolization Combined with 125I Seed Implantation for Non-Small-Cell Lung Cancer"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8847-7115","authenticated-orcid":true,"given":"Peng","family":"Xie","sequence":"first","affiliation":[{"name":"Sixth Medical Center of PLA General Hospital, Beijing 100048, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3258-615X","authenticated-orcid":true,"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"China-Japan Friendship Hospital, Beijing 100048, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidong","family":"He","sequence":"additional","affiliation":[{"name":"Sixth Medical Center of PLA General Hospital, Beijing 100048, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"doi-asserted-by":"publisher","key":"1","DOI":"10.1016\/j.ccm.2019.10.001"},{"doi-asserted-by":"publisher","key":"2","DOI":"10.3322\/caac.21338"},{"doi-asserted-by":"publisher","key":"3","DOI":"10.3322\/caac.21551"},{"doi-asserted-by":"publisher","key":"4","DOI":"10.1038\/nrc3775"},{"doi-asserted-by":"publisher","key":"5","DOI":"10.1007\/s00408-020-00407-5"},{"doi-asserted-by":"publisher","key":"6","DOI":"10.1080\/17476348.2020.1701439"},{"doi-asserted-by":"publisher","key":"7","DOI":"10.3389\/fcell.2021.768943"},{"doi-asserted-by":"publisher","key":"8","DOI":"10.47391\/JPMA.1442"},{"doi-asserted-by":"publisher","key":"9","DOI":"10.1038\/s41467-020-19116-x"},{"doi-asserted-by":"publisher","key":"10","DOI":"10.1097\/JTO.0000000000000559"},{"doi-asserted-by":"publisher","key":"11","DOI":"10.1136\/thoraxjnl-2014-206677"},{"doi-asserted-by":"publisher","key":"12","DOI":"10.1016\/j.ejca.2016.03.081"},{"doi-asserted-by":"publisher","key":"13","DOI":"10.1097\/MLR.0000000000000729"},{"doi-asserted-by":"publisher","key":"14","DOI":"10.3389\/fonc.2020.00057"},{"doi-asserted-by":"publisher","key":"15","DOI":"10.1016\/j.jvir.2021.08.019"},{"doi-asserted-by":"publisher","key":"16","DOI":"10.1016\/j.lungcan.2020.06.010"},{"doi-asserted-by":"publisher","key":"17","DOI":"10.5152\/dir.2020.19371"},{"issue":"5","key":"18","first-page":"1879","article-title":"Clinical analysis of 125I seed implantation combined with epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer","volume":"26","author":"X. Wang","year":"2021","journal-title":"Journal of BUON"},{"doi-asserted-by":"publisher","key":"19","DOI":"10.21037\/jtd-20-2666"},{"doi-asserted-by":"publisher","key":"20","DOI":"10.5114\/jcb.2021.106241"},{"doi-asserted-by":"publisher","key":"21","DOI":"10.4103\/jpgm.JPGM_409_18"},{"issue":"11","key":"22","first-page":"13108","article-title":"Clinical efficacy and safety of crizotinib and alectinib in ALK-positive non-small cell lung cancer treatment and predictive value of CEA and CA125 for treatment efficacy","volume":"13","author":"Z. Li","year":"2021","journal-title":"American Journal of Translational Research"},{"doi-asserted-by":"publisher","key":"23","DOI":"10.1016\/j.omtn.2019.06.002"},{"doi-asserted-by":"publisher","key":"24","DOI":"10.3892\/mmr.2020.11553"}],"container-title":["Computational and Mathematical Methods in Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/3472982.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/3472982.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/3472982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T23:38:12Z","timestamp":1657755492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/cmmm\/2022\/3472982\/"}},"subtitle":[],"editor":[{"given":"Pan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":24,"alternative-id":["3472982","3472982"],"URL":"https:\/\/doi.org\/10.1155\/2022\/3472982","relation":{},"ISSN":["1748-6718","1748-670X"],"issn-type":[{"type":"electronic","value":"1748-6718"},{"type":"print","value":"1748-670X"}],"subject":[],"published":{"date-parts":[[2022,7,13]]}}}